Stratification of responders towards eculizumab using a structural epitope mapping strategy

The complement component 5 (C5)-binding antibody eculizumab is used to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical haemolytic uremic syndrome (aHUS). As recently reported there is a need for a precise classification of eculizumab responsive patients to allow for a safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Volk, Anna-Luisa, Hu, Francis Jingxin, Berglund, Magnus M., Nordling, Erik, Strömberg, Patrik, Uhlen, Mathias, Rockberg, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980765/
https://www.ncbi.nlm.nih.gov/pubmed/27509843
http://dx.doi.org/10.1038/srep31365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980765/
https://www.ncbi.nlm.nih.gov/pubmed/27509843
http://dx.doi.org/10.1038/srep31365

Ejemplares similares